Sotera Health (SHC) has just opened Q1 2026 reporting with trailing numbers that show total revenue of about US$1.2b over the last 12 months and basic EPS of US$0.27, alongside year over year earnings growth of 75.8%. Over the past reported quarters, revenue has ranged from US$254.5 million in Q1 2025 to US$311.3 million in Q3 2025, while quarterly basic EPS moved from a loss of US$0.05 in Q1 2025 to US$0.17 in Q3 2025, illustrating improving profit conversion as trailing net margin sits at 6.7% versus 4% a year earlier.

See our full analysis for Sotera Health.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the dominant stories around growth, risk, and quality that investors have been using to frame Sotera Health.

Margins Improve With 6.7% Net Profit Level

• On a trailing 12 month basis, Sotera Health converted US$1.2b of revenue into US$77.9 million of net income, which works out to a 6.7% net margin compared with 4% last year.
• Bulls point out that higher margins can fit with their view of stronger earnings quality, yet the current 6.7% margin is still far below the bullish assumption that profit margins could eventually reach 18.3%. This highlights a clear gap between recent profitability and the optimistic long term margin story.
  • The bullish narrative leans on regulatory driven testing demand and pricing power at Sterigenics and Nordion. However, the actual trailing margin still reflects the impact of items like the US$112.6 million one off loss.
  • Supporters of the bullish view may take comfort from the 75.8% earnings growth over the last year, but that growth rate sits on a relatively modest margin base. This leaves less room for error if those drivers soften.

Bulls who think the recent 75.8% earnings growth is just the starting point may want to see how that stacks up against a detailed upside case in the 🐂 Sotera Health Bull Case.

High P/E Meets Interest Coverage Risk

• The stock trades on a trailing P/E of 56.1x, above the Global Life Sciences industry average of 36.5x and close to the peer average of 58.1x. At the same time, interest payments are described as not well covered by earnings, which flags a meaningful balance sheet risk alongside that valuation.
• Bears focus on this combination of a high multiple and weak interest coverage, arguing that even with 75.8% trailing earnings growth, the capital structure and funding needs could limit how much of that growth ultimately benefits shareholders.
  • Critics highlight that a large US$112.6 million one off loss has already affected reported results and that guidance points to interest expense of about US$154 million to US$158 million for 2025, both of which compete with earnings for cash.
  • The mixed valuation picture is another focus. The share price of US$15.33 sits below both the DCF fair value of about US$21.95 and the analyst target of US$20.50, which gives bears a reason to question whether current pricing really offers enough compensation for those financial risks.

If you are weighing that high P/E against the debt and legal overhang, it is worth seeing how skeptics frame the downside in the 🐻 Sotera Health Bear Case.

DCF Gap Versus Analyst Target

• At a share price of US$15.33, the stock sits about 30.2% below the stated DCF fair value of roughly US$21.95 and below the analyst price target of US$20.50, while forecasts in the data point to earnings growth of about 14.8% per year and revenue growth of about 5.9% per year.
• Analysts' consensus view leans on that projected 14.8% earnings growth and improving margins. However, the fact that revenue growth forecasts in the data, at around 5.9% annually, sit below the 11.2% broader US market estimate suggests that the valuation gap is more about earnings efficiency than rapid top line expansion.
  • Consensus narrative notes that a 6.7% net margin today would need to move toward a much higher level to match their future profit assumptions, which makes the quality and repeatability of the recent 75.8% earnings growth a key question.
  • What stands out is that the same trailing results that support a DCF fair value above the market price also include the US$112.6 million one off loss and flagged interest coverage risk. Investors may therefore want to separate the core business trajectory from these items when judging the gap between US$15.33 and US$20.50.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Sotera Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Feeling that the story here is finely balanced between risk and reward? Move quickly from headlines to hard numbers and build your own view with the 4 key rewards and 2 important warning signs.

See What Else Is Out There

Despite the 75.8% earnings growth, Sotera Health still has a high P/E, pressured interest coverage and a one-off US$112.6 million loss.

If that mix of valuation pressure and balance sheet strain feels uncomfortable, use the 72 resilient stocks with low risk scores to quickly focus on companies with more resilient profiles and steadier cushions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.